Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 6990.HK | 9926.HK | 1167.HK | 9995.HK | SMZ1.F | 688062.SS | |
|---|---|---|---|---|---|---|
| Market cap | 110.38B | 80.92B | 3.85B | 40.23B | 11.09B | 10.13B |
| P/E (TTM) | 641.4 | — | 6.6 | 6.1 | 31.2 | — |
| Forward P/E | 141.1 | 60.4 | -167.5 | 46.7 | — | -21.6 |
| Price/book | 17.2 | 8.1 | 2.4 | 3.8 | 2.6 | 14.1 |
| Dividend yield | — | — | — | — | 2.90% | — |
| 1-year change | +1.89% | −27.63% | −32.34% | −19.94% | −23.60% | −51.34% |
| Today | +4.39% | +6.48% | +3.58% | +1.49% | +1.45% | +5.29% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 6990.HK news ›Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Windward Bio Form Alliance for SKB378/WIN378 Asthma Clinical Development
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that its partner, Windward Bio, has reported positive interim results from the Phase 2 portion of the POLARIS-1 clinical trial, which... Sichuan Kelun-Biotech Biopharmaceutical…
Sichuan Kelun-Biotech Biopharmaceutical Announces Results From Phase III Study Of Trastuzumab Botidotin Versus T-DM1 In HER2-Positive Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that results from the phase III registrational study of its novel human epidermal growth factor receptor 2 -targeted antibody?drug conjugate...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.: Relative Strength Chart - Stock Hong Kong S.E.
Compare Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. with the company of your choice via a Relative Strength chart. Real-time 6990 price, Hong Kong S.E. stock exchange Relative Strength Chart Sichuan Kelun-Biotech Biopharmaceutical…
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Presents Multiple Study Results at ESMO Congress
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. presented results from multiple clinical studies at the congress, including data from its trophoblast cell-surface antigen 2 -directed antibody-drug...
Sichuan Kelun-Biotech Biopharmaceutical Announces Acceptance Of New Indication Application For Sacituzumab Tirumotecan As First-Line Treatment For Advanced TNBC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that a new indication application of its trophoblast cell-surface antigen 2 -directed antibody drug conjugate sacituzumab tirumotecan has... Sichuan Kelun-Biotech…
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces New Indication Application for Core Product TROP2 ADC Sacituzumab Tirumotecan
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that a new indication application of its trophoblast cell-surface antigen 2 -directed antibody drug conjugate sacituzumab tirumotecan has... Sichuan Kelun-Biotech…
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Presents Results of Phase Iii Optitrop-Lung06 Study of Sacituzumab Tirumotecan as Esmo Oral Presentation and Publishes in the New England Journal of Medicine
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, the results of the Phase III OptiTROP-Lung06 study ... Sichuan Kelun-Biotech…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.